KENINGFORD PARTNERS

CAPITAL ADVISORY

SECTOR PRIMER · TECHNOLOGY & LIFE SCIENCES

2026 Biotech & Life Sciences Financing Landscape

How growth-stage biotech and deep-tech companies are positioning for institutional capital across venture crossover, strategic capital, and project finance.

FEBRUARY 2026 · KENINGFORD PARTNERS RESEARCH

keningfordpartners.com

Biotech and life sciences financing in 2026 is defined by a shift in what investors underwrite. The science still opens the door, but capital now flows to companies that can demonstrate commercialization credibility: realistic timelines, defensible offtake or reimbursement assumptions, and governance ready for institutional scrutiny. This primer outlines the financing pathways available to growth-stage biotech and deep-tech companies and the preparation each pathway demands.

SECTION 01 OF 06

The Diligence Shift: From Science Risk to Execution Risk

Investor diligence has moved decisively toward commercialization questions. Platform breadth and publication pedigree remain necessary, but they no longer carry a raise on their own.

- Commercialization timelines are stress-tested against regulatory precedent, not management ambition; a credible eighteen-month plan outperforms an aspirational nine-month one.
- Offtake credibility, whether pharma partnership, health-system contract, or government procurement, is underwritten as revenue quality, with counterparty and termination analysis.
- Reimbursement pathway analysis has moved from an appendix item to a first-meeting topic for anything touching clinical delivery.
- Data-room quality and KPI discipline are read as proxies for how the company will handle regulatory and partner scrutiny.

SECTION 02 OF 06

Venture Crossover and Growth Equity

The crossover investor base that fueled the last cycle has returned selectively, concentrated in assets with near-term value inflection points.

- Crossover appetite concentrates on companies within eighteen months of a registrational readout or first commercial revenue.
- Insiders are anchoring a growing share of growth rounds, with external leads validating rather than setting terms.
- Structured equity, tranched closes tied to milestones, and warrant coverage appear more frequently in place of straight preferred.

SECTION 03 OF 06

Strategic Capital and Partnerships

Strategic capital is playing a larger role alongside traditional growth equity, and for many companies it is the superior instrument: it validates the science, funds development, and defers dilution.

- Pharma and medtech corporate venture arms increased early-stage activity, frequently pairing equity with option-to-license structures.
- Milestone-based partnership payments funded development programs that equity markets would have priced punitively.
- The negotiation focus has shifted to control terms: exclusivity scope, data rights, and change-of-control provisions determine whether strategic capital helps or constrains the next round.

SECTION 04 OF 06

Project-Level and Infrastructure-Style Financing

For capital-intensive scale-up assets, biomanufacturing capacity, GMP facilities, diagnostic networks, project-level financing has gained real traction, importing infrastructure discipline into life sciences.

- Facility-level debt against contracted capacity reduced equity burn for platform companies building physical scale.
- Government co-funding programs in the US, EU, and Gulf states funded strategic-capacity projects on terms no private instrument matches.
- The prerequisite is contract quality: project finance underwrites the offtake, not the science.

SECTION 05 OF 06

Preparing for a 2026 Raise

Companies that cleared the market efficiently in the past year shared a preparation pattern: a data room built around commercialization evidence rather than publications, a financial model that separates platform spend from program spend, governance and reporting upgraded a full round earlier than felt necessary, and a financing strategy that sequenced strategic, project, and equity capital deliberately rather than defaulting to the next preferred round.

SECTION 06 OF 06

Methodology

Compiled from sector mandates, investor feedback, and public market comparables as of Q1 2026. For informational purposes only.

NEXT STEP

Discuss this with our team

Keningford Partners is a New York-based, principal-led capital advisory and M&A firm advising companies from Series A through the pre-IPO stage, alongside institutional investors, on equity, debt, and strategic transactions. Every mandate is led directly by senior bankers from origination through close.

EMAIL

info@keningfordpartners.com

PHONE

+1 (315) 932-6269

OFFICE

136 Madison Ave, 7th Floor, New York, NY 10016, USA

WEB

keningfordpartners.com